ProtAffin AG Granted Patent in USA For Lead Anti-inflammatory Product PA401
Whereas wild-type chemokines are over-expressed in many chronic and acute inflammatory diseases, ProtAffin has developed anti-inflammatory variants of IL-8 with increased affinity for glycan structures found on inflamed endothelium. These anti-inflammatory products do not activate chemokine receptors found on leukocytes.
Dr. Jason Slingsby, CEO of ProtAffin commented: “We are very happy that the US Patent Office has granted us claims protecting our lead anti-inflammatory product PA401, and we were granted a similar patent earlier in 2009 by the European Patent Office. There is an urgent clinical need for biopharmaceuticals which can help patients with chronic lung inflammation in the USA and EU and this patent grant in the USA is an important step in commercialising PA401.”
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.